Dementia tops Australia's death toll. A blood test just got the green light.

What just happened

Dementia has overtaken coronary heart disease to become the leading cause of death in Australia, according to new data published this week in MJA Insight+. One in ten deaths in Australia is now attributable to dementia — a condition affecting 446,500 Australians, cared for by 1.7 million people, and projected to reach 1.1 million without intervention by 2066.

The shift did not happen overnight. Dementia rising to the top of the mortality table reflects a demographic reality that the healthcare system has not matched with investment. As Dementia Australia’s chief executive put it: “Investment in dementia-specific services and supports have not kept pace.”

In the same news cycle, the TGA authorised the pTau217 blood test for use in Australian clinical trials. This test can detect the hallmark protein changes of Alzheimer’s disease — phosphorylated tau and amyloid pathology — up to 20 years before clinical symptoms appear. Clinical assays, processed through the Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis, are provisionally expected from October 2026.

Two stories. One week. They belong together.

Both-and

The magnitude of dementia is not a policy abstraction

One in ten deaths is a number with weight. Coronary heart disease — a condition that receives substantial research funding, multiple established pharmacological interventions, and primary prevention infrastructure across general practice — has now been surpassed by a condition for which there is no cure, no routine early detection, and a care system chronically underfunded relative to the burden.

For a 45-year-old reading this, the statistic is also personal in a statistical sense. Women carry a disproportionate share of dementia’s burden — both as people who develop it at higher rates than age-matched men across the full lifespan, and as the informal carers who absorb the majority of unpaid care as the disease progresses. The Dementia Australia figure that up to 45% of dementia cases may be preventable or delayable through modifiable risk factors offers genuine cause for action rather than resignation. That percentage assumes maximal uptake of interventions — it is not a guarantee — but the magnitude of the modifiable fraction is real.

The blood test is significant — and its limits are clear

The pTau217 test is the second Alzheimer’s blood biomarker to receive TGA authorisation in Australia, following an earlier pTau181 test. Its sensitivity and specificity in the right clinical context are comparable to PET scanning and cerebrospinal fluid testing — the current gold standards — but without the cost and access barriers. A blood test that performs comparably is genuinely useful for a healthcare system trying to get more people into trials, or to confirm a working clinical diagnosis in a specialist memory context.

But the caveats are clear. Dr Stephanie Daly, speaking to the RACGP on the authorisation, gave direct guidance: GPs need education before implementing these tests; the test detects only Alzheimer’s pathology — one cause among many of dementia — not all neurodegenerative conditions; and crucially, the test should not be used in asymptomatic people. The accuracy of pTau217 in people with no cognitive symptoms is simply not known.

This is not the “home test for Alzheimer’s” story that tends to circulate on social media. It is a specialist-context diagnostic tool, currently authorised for clinical trials, with broader clinical use pending. That is still significant — but it is a different thing.

What the test cannot yet answer

Even a highly accurate blood test raises questions that medicine cannot yet fully resolve. If a 48-year-old woman with memory concerns receives a positive pTau217 result — confirming the presence of Alzheimer’s pathology, likely 15 or more years before clinical dementia — what does she do with that information?

The disease-modifying therapeutics for Alzheimer’s that have emerged from the last decade of research are promising but not yet in standard Australian clinical practice for most people. The psychological weight of an early positive result, in the absence of established disease-modifying treatment, is a genuine ethical and clinical challenge. The biomarker and the clinical pathway have to develop together — and the RACGP guidance is to move deliberately, train clinicians, and not race ahead of what the system can support safely.

My two cents

The dementia statistic is not an invitation to despair. The modifiable risk factors are specific and actionable: blood pressure management, regular physical movement, not smoking, limiting alcohol, treating hearing loss early, managing depression, staying socially connected, and protecting against head injury. These are things any 45-year-old can audit right now, with or without a blood test.

For women particularly: the risk of developing Alzheimer’s over a lifetime is higher, the caregiving burden is heavier, and the healthcare conversation tends to arrive later than it should. If you haven’t talked with your GP about brain health, cognitive risk, and which of the modifiable factors apply to your own profile, this week’s data is a reasonable prompt to do that.

The blood test is worth following. It will be part of general practice eventually. For now, what matters is that the tool exists, is being developed carefully, and the window before symptoms — which for many people opens in their forties — is exactly when lifestyle changes most likely matter.

Verdict: yes — a genuine clinical milestone paired with a sobering population statistic. Both deserve a place in the conversation.

---

Sources cited

1. Dementia now the leading cause of death in Australia. MJA Insight+, 17 August 2026. https://insightplus.mja.com.au/2026/32/dementia-now-the-leading-cause-of-death-in-australia
2. ‘Milestone’ Alzheimer’s diagnosis blood test gets green light. newsGP, RACGP, 2026. https://www1.racgp.org.au/newsgp/clinical/milestone-in-alzheimer-s-diagnosis-as-new-blood-te
3. About dementia. Dementia Australia. https://www.dementia.org.au/information/about-dementia